Clinical Trials Logo

Clinical Trial Summary

This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04866056
Study type Interventional
Source Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Contact
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date May 2021
Completion date May 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04313881 - Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Phase 3
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04485065 - Safety and Efficacy of IBI188 With Azacitidine in Newly Diagnosed Higher Risk MDS Phase 1
Recruiting NCT04701229 - Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Recruiting NCT04174547 - An European Platform for Translational Research in Myelodysplastic Syndromes
Enrolling by invitation NCT04093570 - An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) Phase 2
Completed NCT02508870 - A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Phase 1
Recruiting NCT04543305 - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1
Suspended NCT04187703 - 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies Early Phase 1
Recruiting NCT03291444 - CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS Phase 1
Not yet recruiting NCT04823624 - MBG453 in Lower Risk MDS Phase 2
Completed NCT02909972 - Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Phase 1
Recruiting NCT02488408 - A Phase Ib/II Multicenter Open-label Study of BGB324 in Patients With AML or MDS Phase 1/Phase 2
Terminated NCT02243124 - A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) Phase 1
Not yet recruiting NCT01417767 - Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS Phase 2/Phase 3
Completed NCT01164163 - INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Phase 1
Recruiting NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Active, not recruiting NCT01137825 - Registry of Older Patients With Cancer